BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies
August 5, 2024 4:01 PM EDTJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $11.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "Focus heading into 2Q was on Orladyo sales, and BCRX delivered another commercial surprise (stock +5.5%) and increased guidance due to... More
